J Wilensky, RG Fiscella, AM Carlson, LS … - American journal of ophthalmology, 2006 - Elsevier Glaucoma patients in the IMS Health LifeLink database with a pharmacy claim for
latanoprost (n = 1567), travoprost (n = 381), or bimatoprost (n = 476) between
September, 2001 and March, 2002 who had no claims for IOP-lowering ... Cited by 37 - Related articles - All 7 versions
DS Friedman, HD Jampel, NG Congdon, R … - American Journal of Ophthalmology, 2007 - Elsevier Five physicians and 20 patients participated. Devices used by physicians
recorded all drops dispensed. Extra readings were recorded when physicians
carried the devices during the day. For patients, 93% of all drops were ... Cited by 10 - Related articles - All 23 versions
PP Lee, JG Walt, TH Chiang, A Guckian, J … - American Journal of Ophthalmology, 2007 - Elsevier Patients with a pharmacy claim for a 2.5 ml bottle of latanoprost, travoprost,
or bimatoprost between September 1, 2002 and December 31, 2002 were identified
from a retail pharmacy database and were followed up for 12 months. Three ... Cited by 4 - Related articles - All 14 versions
JLR FRANZCO, MAA PhD - Clinical & experimental ophthalmology - interscience.wiley.com Methods: This large, population-based, retrospective, cohort study used pharmacy
claims data for concessional patients from the Australian Pharmaceutical
Benefits Scheme (July 1999–June 2005). Resupply rates for prostaglandins, ... Cited by 4 - Related articles - BL Direct - All 4 versions
DB Rein, JS Wittenborn, PP Lee, KE Wirth, … - Ophthalmology, 2009 - Elsevier To estimate the incremental cost-effectiveness of routine glaucoma assessment
and treatment under current eye care visit and treatment patterns and different
levels of treatment effectiveness (from randomized trials). Cited by 3 - Related articles - All 4 versions
WC Stewart, JA Stewart, MA Mychaskiw - Eye, 2007 - nature.com Over the life of the model latanoprost was less expensive than timolol by
5.3–7.6% (Scandinavia) and 2.1% (UK). Following adjustments, therapy in the
original timolol-treated cohort was slightly more effective in each country ... Cited by 3 - Related articles - All 4 versions
- ►iovs.org SY Ghoghawala, MJ Mannis, CE Pullar, MI … - Investigative ophthalmology & visual science, 2008 - ARVO RESULTS. The β-AR agonist isoproterenol decreased AMCE cell migratory speed to
70% of untreated controls, and this was correlated with a 0.60-fold decrease in
levels of activated phospho-ERK (P-ERK). Treatment with the β-AR ... Cited by 2 - Related articles - BL Direct - All 3 versions
CG Owen, IM Carey, S de Wilde, PH Whincup … - Eye, 2008 - nature.com Percentage persistent at 1-year rose after 1997 when prostaglandins were
introduced; from 61% in 1994–1996 to 70% in 2002–2004. Persistence with any
treatment did not differ between those initiated on -blockers compared to ... Cited by 1 - Related articles - All 2 versions
CE Pullar, CG Manabat-Hidalgo, RS Bolaji, RR … - Pharmacological Research, 2008 - Elsevier Adrenergic receptors and their downstream effector molecules are expressed in
all cell types in the skin, and it is only recently that functionality of the
catecholamine agonist activated signaling in the cutaneous repair process ... Cited by 2 - Related articles - All 3 versions
MQ Rahman, DMI Montgomery, MN … - British Medical Journal, 2009 - bjo.bmj.com Online First articles must include the digital object identifier (DOIs) and date
of initial publication. establish publication priority; they are indexed by
PubMed from initial publication. Citations to may be posted when available ... Related articles - All 3 versions
